Answers are grounded in this paper and cite their sources.
Analysis uncovers predictive biomarkers for relapse risk in children with nephrotic syndrome, suggesting tailored Rituximab treatment strategies.
Baseline memory B-cell and NK-cell levels (pre-RTX), as well as IgG levels at 3 months post-RTX, were identified as predictive biomarkers for the 2-year relapse risk following RTX therapy. These findings may contribute to the development of personalized RTX treatment strategies.
No takes yet. Share an insight, caveat, or question.
Ling et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: